BioAge Labs (BIOA) Non-Current Assets (2023 - 2026)
BioAge Labs' (BIOA) quarterly Non-Current Assets came in at $66.6 million in Q2 2026, up 225.74% year-over-year from $20.5 million in Q2 2025, and up 1049.76% quarter-over-quarter from $5.8 million in Q1 2026.
Analysis
BioAge Labs (BIOA) Non-Current Assets (2023 - 2026) Analysis & Trends
BioAge Labs has disclosed Non-Current Assets across 4 years of filings, most recently posting $66.6 million for Q2 2026.
- In Q2 2026, Non-Current Assets rose 225.74% year-over-year to $66.6 million; the TTM figure through Jun 2026 stood at $94.8 million (up 128.23% YoY), while the FY2025 annual figure was $8.1 million, up 615.83% from the prior year.
- Non-Current Assets came in at $66.6 million for Q2 2026 at BioAge Labs, up from $5.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $66.6 million in Q2 2026 to a low of $618000.0 in Q4 2023.
- Average Non-Current Assets over 4 years is $15.2 million, with a median of $8.1 million recorded in 2025.
- Year-over-year, Non-Current Assets jumped 1460.39% in 2025 and plunged 69.55% in 2026.
- Over 4 years, Non-Current Assets stood at $618000.0 in 2023, then soared by 83.01% to $1.1 million in 2024, then soared by 615.83% to $8.1 million in 2025, then surged by 722.84% to $66.6 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $66.6 million in Q2 2026, $5.8 million in Q1 2026, and $8.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 564.41 Mn |
| 10 | BioAge Labs | 409.83 Mn | 409.83 Mn | -14.23 Mn | 66.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66.62 Mn |
| Mar 31, 2026 | 5.79 Mn |
| Dec 31, 2025 | 8.10 Mn |
| Sep 30, 2025 | 14.26 Mn |
| Jun 30, 2025 | 20.45 Mn |
| Mar 31, 2025 | 19.03 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | 914,000.00 |
| Dec 31, 2023 | 618,000.00 |